期刊文献+

他汀类药物的多效性作用及其临床意义 被引量:1

Pleiotropic Effects of Statins and Their Clinical Significance
下载PDF
导出
摘要 他汀类药物(statins)即3-羟基3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂可明显降低心血管事件的发生率和死亡率,是目前临床上应用最广的降胆固醇药物。近年大量实验及临床研究资料显示,他汀类药物除具有显著的降血脂作用外,还有独立于降脂外的作用即多效性,在心血管领域,其多效性主要包括改善血管内皮功能、抑制炎症、抑制平滑肌细胞的增生和促进凋亡、抑制血栓形成和稳定斑块等。然而这些多效性作用在临床治疗中是否具有实际临床获益尚不十分清楚。
出处 《中国分子心脏病学杂志》 CAS 2006年第5期289-291,共3页 Molecular Cardiology of China
  • 相关文献

参考文献22

  • 1[1]Laufs U,Liao JK.Isoprenoid metabolism and the pleiotropic effect of statins.Curr Atherosclerocs Rep,2003,5 (5):372-378.
  • 2[2]Weitz-Schmidt G,Welzenbach K,Brinkmann V,et al.Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.Nat Med,2001,7(6):687-692.
  • 3[3]Wassmann S,Faul A,Hennen B,et al.Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.Circ Res,2003,93(9):98-103.
  • 4[4]Karatzis E,Lekakis J,Papamichael C,et al.Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina.Int J Cardiol,2005,101 (1):65-70.
  • 5[5]Landmesser U,Bahlmann F,Mueller M,et al.Simvastatin versus ezetimibe:pleiotropic and lipid-lowering effects on endothelial function in humans.Circulation,2005,111 (18):2356-2363.
  • 6[6]Meng CQ.Atherosclerosis is an Inflammatory Disorder After All.Curr Top Med Chem,2006,6(2):93-102.
  • 7[7]Rosenson RS,Tangney CC,Casey LC.Inhibition of proinflammatory cytokine production by pravastatin.Lancet,1999,353 (9157):983-984.
  • 8王平,楚建民,宋执敬.辛伐他汀对正常血脂水平急性冠状动脉综合征患者早期炎症因子的干预观察[J].中国分子心脏病学杂志,2006,6(2):78-80. 被引量:3
  • 9[9]Negre-Aminou P,van Vliet AK,van Erck M,et al.Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.Biochim Biophys Acta,1997,1345(3):259-268.
  • 10[10]Erl W.Statin-induced vascular smooth muscle cell apoptosis:a possible role in the prevention of restenosis? Curr Drug Targets Cardiovasc Haematol Disord,2005,5(2):135-144.

二级参考文献10

  • 1李建军.炎症可能是联接高血压和动脉粥样硬化的桥梁[J].中国分子心脏病学杂志,2005,5(1):385-388. 被引量:29
  • 2[5]Plutzky J.Infalmmatory pathways in atherosclerosis and acute coronary syndromes.Am J Cardiol,2001,88:10k-15k.
  • 3[6]RidkerPM,RifaiN,Pfeffer MA,etal.Long term effects of pravastatin on plasma concentration of C-reactive protein.The Cholesterol and Recurrent Events (CARE) investigators.Circulation,1999,100(3):230-235.
  • 4[7]Rajavashisth TB,Xu Xp,Jovinge S,et al.Membrane type / matrix metalloproteinase expression in human atherosclerotic plaques:evidence for activation by proinflammatory mediators.Circulation,1999,99:3103-3109.
  • 5[8]Yasojima K,Schwab C,Edith G,et al.Generation of c-reactive protein and complements components in atherosclerotic plaques.Am J Pathol,2001,158:1039-1051.
  • 6[9]Andrie R,Maylahn M,Braun P,et al.C-reactive protein in coronary plaques prevalence with acute coronary syndrome.Z Kardiol,2002,91:913-920.
  • 7[11]Rosenson RS,Tangney CC,Casey LC,et al.Inhibition of proinflammatory cytokine production by pravastatin.Lancet,1999,353:983-984.
  • 8[1]Li JJ.Silent myocardial ischemia may be related to inflammatory response.Med Hypotheses,2004,62:252-256.
  • 9[3]ACC/AHA Guidelines for the management of patients with unstable angina and Non-ST-Segment elevation myocardial infarction.A report of American College of Cardiology/American Heart Association Task Force of Practice Guidelines.J Am coll Cardiol,2000,36:970-1062.
  • 10方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067

共引文献2

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部